Historical Context & Motivation
Before the rise of large-scale pharmaceutical manufacturing, virtually every medication dispensed by a pharmacist was a compounded preparation. Apothecaries blended powders, mixed ointments, and formulated elixirs individually for each patient. The industrial revolution brought mass production, yet the need for individualized therapy never disappeared. Patients who cannot swallow tablets, who require dosage strengths unavailable commercially, or who are allergic to excipients in manufactured products still depend on nonsterile compounding to receive appropriate care. Understanding the historical evolution of compounding regulations helps pharmacists appreciate why current standards—particularly those set by the United States Pharmacopeia (USP)—exist and how they protect both practitioners and patients.
The central question driving modern nonsterile compounding is this: How can pharmacists prepare individualized, non-commercially-available dosage forms while ensuring they meet the same rigorous standards of identity, strength, quality, and purity that patients expect from manufactured products? The remaining sections of this lesson address that question through the lens of USP ⟨795⟩, pharmaceutical calculations, and practical compounding technique.
Core Principles & Definitions
Nonsterile compounding encompasses the preparation of dosage forms that do not require sterility, including capsules, solutions, suspensions, ointments, creams, suppositories, and troches. The governing standard, USP General Chapter ⟨795⟩, applies to all healthcare settings—community pharmacies, hospitals, and physician offices—where personnel prepare nonsterile compounded preparations for human or animal use. Several foundational concepts underpin every aspect of this practice.
Master Formulation Record (MFR)
Compounding Record (CR)
Beyond-Use Date (BUD)
Component Verification
Standard Operating Procedures (SOPs)
Visual Explanation — Compounding Workflow
The workflow depicted above emphasizes that nonsterile compounding is not a single act of mixing ingredients—it is a systematic process governed by documentation at every step. The Master Formulation Record (MFR) provides the standardized procedure for a given preparation, while the Compounding Record (CR) captures the unique details of each batch. Quality checks—visual inspection, weight verification, and organoleptic assessment—function as in-process controls. Only after a pharmacist performs final verification is the preparation deemed suitable for dispensing. This redundancy mirrors the check systems used in manufacturing and protects against compounding errors that could endanger patients.
Pharmaceutical Calculations for Compounding
Accurate pharmaceutical calculations are the mathematical backbone of nonsterile compounding. Errors in arithmetic or unit conversion can lead to subtherapeutic or toxic preparations. The following equations represent the most commonly applied formulas in daily compounding practice.
Dosage Form Classification & BUD Assignment
Nonsterile compounded preparations span a wide array of dosage forms, each with unique physical characteristics, stability considerations, and patient administration requirements. USP ⟨795⟩ categorizes compounded preparations by their beyond-use date (BUD) based on the type of formulation, availability of stability data, and whether aqueous ingredients are present. The revised USP ⟨795⟩ establishes default BUDs when preparation-specific stability data are not available, with the requirement that stability-indicating studies can extend these defaults.
| Dosage Form | Route of Administration | Key Considerations | Default BUD |
|---|---|---|---|
| Capsules | Oral | Geometric dilution for potent APIs; weight variation ≤ ±10% of average | 180 days |
| Oral suspensions | Oral | Uniform particle size; "Shake Well" auxiliary label; wetting agent may be needed | 14 days (refrigerated) |
| Topical ointments | Topical | Levigation with ointment slab or electronic mortar; incorporate API uniformly | 90 days |
| Suppositories | Rectal / Vaginal | Mold calibration required; displacement factor calculation essential | 180 days (non-aqueous) |
| Troches / Lozenges | Oral (buccal dissolution) | Polyethylene glycol (PEG) or silicone molds; flavoring agents for palatability | 180 days |
Worked Example — Compounding Progesterone Capsules
A prescriber writes an order for progesterone 200 mg capsules, #30, for a patient undergoing hormone replacement therapy. The pharmacy's Master Formulation Record specifies the use of micronized progesterone powder with Avicel PH-101 (microcrystalline cellulose) as the diluent. The MFR calls for a 10% excess to account for compounding losses. The target capsule shell size is #1, with a capacity of approximately 400 mg of powder.
Quality Assurance, Strengths & Limitations
Nonsterile compounding occupies a unique niche in pharmacy practice, offering customization that commercial manufacturing cannot match, yet carrying inherent limitations related to scale, reproducibility, and regulatory oversight. A clear-eyed assessment of both the advantages and challenges helps compounding pharmacists maintain the highest standard of patient care.
| Strengths | Limitations |
|---|---|
| Provides patient-specific dosing (pediatric, geriatric, veterinary) not available commercially | Shorter BUDs compared to commercially manufactured products |
| Allows removal of allergens, dyes, or preservatives problematic for individual patients | No FDA pre-market review; relies on compounder competency and state board oversight |
| Addresses drug shortages by compounding from bulk APIs when approved products are unavailable | Batch-to-batch variability is higher than industrial GMP manufacturing |
| Enables alternative dosage forms (liquid from tablet, topical from oral) for dysphagia or noncompliance | Limited analytical testing capability in most community pharmacy settings |
| Supports orphan disease populations and combination therapies | Potential for contamination if SOPs, training, or environmental controls are inadequate |
Quality Assurance Measures
- Weight variation testing: For capsules, weigh a minimum of 10% of the batch; individual weights should not deviate more than ±10% from the average capsule weight.
- Visual and organoleptic inspection: Assess color uniformity, absence of particulate matter, appropriate texture, and consistency with expected characteristics.
- pH testing: For aqueous preparations, verify pH falls within the acceptable range for stability and patient comfort.
- Equipment calibration: Balances must be calibrated and verified per facility SOP; Class III prescription balances have a minimum weighable quantity based on their sensitivity requirement.
Regulatory Framework — USP ⟨795⟩ vs. ⟨797⟩ and 503A vs. 503B
Pharmacy compounding exists within a complex regulatory ecosystem that distinguishes between nonsterile and sterile preparations, as well as between traditional compounding pharmacies and outsourcing facilities. Understanding these distinctions is essential for NAPLEX preparation and daily pharmacy practice. The two most critical regulatory frameworks are the USP general chapters and the federal DQSA sections.
| Feature | USP ⟨795⟩ — Nonsterile | USP ⟨797⟩ — Sterile |
|---|---|---|
| Scope | Oral, topical, rectal, vaginal, and other non-injectable routes | Injectables, ophthalmic, inhalation, and other forms requiring sterility |
| Environment | Dedicated compounding area; environmental controls not as stringent | ISO-classified cleanrooms, PECs (e.g., laminar airflow hoods), strict air quality monitoring |
| Garbing | Clean clothing, gloves, hair containment | Full gowning, sterile gloves, face masks, shoe covers, goggles |
| BUD Defaults | Up to 180 days (solids) / 14 days (aqueous) / 90 days (nonaqueous) | Ranges from 1 hour (immediate use) to 45 days based on risk category |
| Testing | Visual inspection, weight variation, pH as applicable | Sterility testing, endotoxin testing, media-fill testing, environmental monitoring |
Section 503A vs. 503B of the DQSA
Under the Drug Quality and Security Act (DQSA) of 2013, Section 503A governs traditional compounding pharmacies that prepare medications pursuant to individual patient prescriptions under the supervision of a licensed pharmacist. These pharmacies are primarily regulated by state boards of pharmacy and must comply with USP ⟨795⟩ or ⟨797⟩. In contrast, Section 503B created a new category of "outsourcing facilities" that may compound without individual prescriptions and distribute to healthcare facilities, but must register with the FDA, comply with current Good Manufacturing Practices (cGMP), and submit to FDA inspections. This dual-track system arose directly from the NECC tragedy and represents Congress's effort to close the regulatory gap between traditional compounding and large-scale drug manufacturing.
Practice Problems
Lesson Summary
Nonsterile compounding is governed by USP General Chapter ⟨795⟩, which establishes standards for personnel training, facility requirements, component verification, Master Formulation Records, Compounding Records, and beyond-use date assignment. Default BUDs depend on dosage form: 180 days for solids, 14 days for aqueous preparations, and 90 days for nonaqueous semisolids, all of which may be extended with preparation-specific stability data.
Essential compounding calculations include percentage strength, alligation alternate, the dilution equation (C₁V₁ = C₂V₂), and excess quantity calculations. Regulatory oversight occurs under Section 503A for traditional pharmacies (state-regulated, patient-specific prescriptions) and Section 503B for outsourcing facilities (FDA-registered, cGMP-compliant). Quality assurance measures—including weight variation testing, visual inspection, and geometric dilution—are critical to ensuring every compounded preparation meets the standard of identity, strength, quality, and purity that patients deserve.